Table 2.
Statistical data and group comparisons for T cell subsets percentage in the cervical lymph nodes of C57BL/6 mice after short-term PE, EE, and PE + EE treatments
| T cell phenotype | Interaction effect | Main effect of age | Main effect of treatment | Vs. Control (%) | Between age groups (%) | Between treatment groups (%) |
|---|---|---|---|---|---|---|
|
CD4+ cells (Fig. 4a) |
NS | NS | NS | NS | NS | NS |
|
CD4+ TN cells (Fig. 4b) |
NS | S (F(2, 60) = 7.445; p < 0.01) | S (F(3, 60) = 3.024; p < 0.05) | 5 m PE + EE > 5 m C (14.6 ± 1.4 vs. 9.7 ± 1.2; p < 0.01) |
5 m PE + EE > 10 m PE + EE (14.6 ± 1.4 vs. 10.1 ± 0.7; p < 0.01) 5 m PE + EE > 15 m PE + EE (14.6 ± 1.4 vs. 9.2 ± 0.7; p < 0.01) |
NS |
|
CD4+ TCM cells (Fig. 4c) |
S (F(6, 62) = 3.497; p < 0.01) | S (F(2, 62) = 9.335; p < 0.001) | NS |
5 m EE > 5 m C (11.1 ± 1.0 vs. 5.7 ± 1.4; p < 0.01) 5 m PE > 5 m C (10.3 ± 0.7 vs. 5.7 ± 1.4; p < 0.05) |
5 m EE > 10 m EE (11.1 ± 1.0 vs. 6.2 ± 0.4; p < 0.01) 5 m EE > 15 m EE (11.1 ± 1.0 vs. 5.6 ± 0.5; p < 0.01) 5mPE > 10 m PE (10.3 ± 0.7 vs. 4.7 ± 1.2; p < 0.01) 5 m PE > 15 m PE (10.3 ± 0.7 vs. 4.6 ± 1.4; p < 0.01) |
5 m EE > 5 m PE + EE (11.1 ± 1.0 vs. 6.4 ± 0.5; p < 0.05) 5 m PE > 5 m PE + EE (10.3 ± 0.7 vs. 6.4 ± 0.5; p < 0.05) |
|
CD4+ TEM cells (Fig. 4d) |
S (F(6, 58) = 3.399; p < 0.01) | S (F(2, 58) = 4.931; p < 0.05) | S (F(3, 58) = 3.324; p < 0.05) |
5 m EE < 5 m C (0.7 ± 0.3 vs. 3.5 ± 0.7; p < 0.01) 5 m PE < 5 m C (0.8 ± 0.4 vs. 3.5 ± 0.7; p < 0.01) |
5 m EE < 15 m EE (0.7 ± 0.3 vs. 2.7 ± 0.2; p < 0.05) 5 m PE < 10 m PE (0.8 ± 0.4 vs. 3.6 ± 0.6; p < 0.01) 5 m PE < 15 m PE (0.8 ± 0.4 vs. 3.4 ± 0.3; p < 0.01 |
5 m EE < 5 m PE + EE (0.7 ± 0.3 vs. 3.1 ± 0.4; p < 0.01) 5 m PE < 5 m PE + EE (0.8 ± 0.4 vs. 3.1 ± 0.4; p < 0.01) |
| CD4+ CD25+ cells (Fig. 4e) | S (F(6, 61) = 3.235; p < 0.01) | NS | NS | 5 m PE > 5 m C (22.7 ± 2.4 vs. 10.7 ± 2.7; p < 0.01) |
5 m PE > 10 m PE (22.7 ± 2.4 vs. 13.0 ± 3.4; p < 0.05) 5 m PE > 15 m PE (22.7 ± 2.4 vs. 12.1 ± 3.4; p < 0.05) |
NS |
|
CD8+ cells (Fig. 5a) |
S (F(6, 61) = 2.286; p < 0.05) | S (F(2, 61) = 5.321; p < 0.01) | S (F(3, 61) = 6.713; p < 0.001) | 15 m EE > 15 m C (37.4 ± 2.3 vs. 25.7 ± 2.9; p < 0.05) |
15 m EE > 5 m EE (37.4 ± 2.3 vs. 20.6 ± 1.8; p < 0.05) 15 m EE > 10 m EE (37.4 ± 2.3 vs. 26.8 ± 3.8; p < 0.01) |
5 m PE + EE > 5 m EE (34.3 ± 1.8 vs. 20.6 ± 1.8; p < 0.01) 5 m PE + EE > 5 m PE (34.3 ± 1.8 vs. 20.7 ± 0.7; p < 0.01) |
|
CD8+ TN cells (Fig. 5b) |
NS | NS | S (F(3, 61) = 8.369; p < 0.0001) |
5 m PE + EE > 5 m C (20.2 ± 0.8 vs. 13.4 ± 1.8; p < 0.05) 15 m EE > 15 m C (18.4 ± 1.8 vs. 10.2 ± 1.7; p < 0.05) 15 m PE + EE > 15 m C (17.6 ± 1.3 vs. 10.2 ± 1.7; p < 0.05) |
5 m EE < 15 m EE (10.7 ± 1.1 vs. 18.4 ± 1.8; p < 0.05) |
5 m PE + EE > 5 m EE (20.2 ± 0.8 vs. 10.7 ± 1.1; p < 0.01) 5 m PE + EE > 5 m PE groups (20.2 ± 0.8 vs. 10.4 ± 1.0; p < 0.01) |
|
CD8+ TCM cells (Fig. 5c) |
NS | S (F(2, 60) = 9.552; p < 0.001) | NS | NS |
15 m C > 10 m C (12.8 ± 1.6 vs. 8.2 ± 0.6; p < 0.05) 15 m EE > 10 m EE (12.8 ± 2.1 vs. 8.4 ± 0.7; p < 0.05) |
NS |
|
CD8+ TEM cells (Fig. 5d) |
S (F(6, 59) = 2.455; p < 0.05; Fig. 5d) | S (F(2, 59) = 3.173; p < 0.05) | NS | NS |
10 m PE > 5 m PE (1.6 ± 0.5 vs. 0.2 ± 0.1; p < 0.05) 15 m PE > 5 m PE (2.0 ± 0.6 vs. 0.2 ± 0.1; p < 0.05) |
NS |
|
CD8+ CD25+ cells (Fig. 5e) |
NS | S (F(2, 62) = 4.2; p < 0.05) | S (F(3, 62) = 3.839; p < 0.05) | NS |
5 m PE + EE < 10 m PE + EE (19.4 ± 3.6 vs. 33.2 ± 1.3; p < 0.05) 5 m PE + EE < 15 m PE + EE (19.4 ± 3.6 vs. 33.7 ± 1.6; p < 0.05) |
10 m PE + EE > 10 m PE (33.2 ± 1.3 vs. 17.2 ± 6.0; p < 0.05) |
S significant, NS not significant, m month, TN naïve T cells, TCM central memory T cells, TEM effector memory T cells